Clinical pharmacokinetics of TNF antagonists: How do they differ?

Seminars in Arthritis and Rheumatism

Volumn 34, Issue 5 SUPPL., 2005, Pages 12-18

  Nestorov, Ivan ^a  

^a ZYMOGENETICS INC   (United States)

Author keywords

Adalimumab; Etanercept; Immunogenicity; Infliximab; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; CHIMERIC ANTIBODY; DRUG ANTIBODY; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR;

ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG SYNOVIAL FLUID LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; MOLECULAR WEIGHT; MULTIPLE DRUG DOSE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; STEADY STATE; TIME;

EID: 17044418491     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2005.01.004     Document Type: Conference Paper

References (30)

1. J.C. Beckham, D.S. Caldwell, B.L. Peterson, A.M. Pippen, M.S. Currie, F.J. Keefe Disease severity in rheumatoid arthritis relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures J Clin Immunol 12 1992 353 361
2. C.Q. Chu, M. Field, M. Feldmann, R.N. Maini Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis Arthritis Rheum 34 1991 1125 1132
3. F. Cornilie, D. Shealy, G. D'Haens, K. Geboes, G. van Assche, J. Ceuppen Infiximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease Aliment Pharmacol Ther 15 2001 463 473
4. M. Schwab, U. Klotz Pharmacokinetic considerations in treatment of inflammatory bowel disease Clin Pharmacokinet 40 2001 723 751
5. P. Rutgeerts, G. D'Haens, S. Targan, E. Vasiliauskas, S.B. Hanauer, D.H. Present Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease Gastroenterology 117 1999 761 769
6. C. Bonifati, F. Ameglio Cytokines in psoriasis Int J Dermatol 38 1999 241 251
7. C. Bonifati, M. Carducci, P. Cordiali Fei, E. Trento, G. Sacerdoti Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients relationships with disease severity Clin Exp Dermatol 19 1994 383 387
8. H.T. Idriss, J.H. Naismith TNF-alpha and the TNF receptor superfamily structure-function relationships Microsc Res Tech 50 2000 184 195
9. HUMIRA™ (adalimumab) Patient Information 2003 Abbott Laboratories North Chicago, IL, USA January
10. R.G. Granneman, Y. Zhang, P.A. Noertersheuser, R.B. Velagapudi, W.M. Awni, C.S. Locke Pharmacokinetic/pharmacodynamic (PK/PD) relationships of adalimumab (HUMIRA™) in rheumatoid arthritis (RA) patients during phase II/III clinical trials 2003 ACR Annual Scientific Meeting; November; Orlando, FL. Poster 256.
11. D.M. Chen, K.B. Gordon, C. Leonardi, M.A. Menter Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis Preliminary findings from a 12-week dose ranging trial 62nd AAD Annual Meeting; February 6-11, 2004; Washington DC. J Am Acad Dermatol 50 suppl 2004 Poster P2.
12. V.M. Awni, P. Cascella, N. Oleka, R.B. Velagapudi, H. Kupper, E. Chartash Steady-state pharmacokinetics (PK) of adalimumab (HUMIRA™) following 40 mg subcutaneous (sc) injection every other week (eow) in rheumatoid arthritis (RA) patients with and without methotrexate (MTX) background therapy 2003 ACR Annual Scientific Meeting; November; Orlando, FL. Poster 255.
13. R.B. Velagapudi, P.A. Noertersheuser, W.M. Awni, H. Kupper, G.R. Granneman, L.B. van de Putte The effect of methotrexate (MTX) coadministration on the pharmacokinetics (PK) of adalimumab (HUMIRA™) following a single intravenous injection to rheumatoid arthritis patients 2003 ACR Annual Scientific Meeting; November, Orlando, FL. Poster 258.
14. ENBREL® (etanercept) Patient Information 2003 Amgen Inc Thousand Oaks, CA, USA July
15. J.M. Korth-Bradley, A.S. Rubin, R.K. Hanna, D.K. Simcoe, M.E. Lebsack The pharmacokinetics of etanercept in healthy volunteers Ann Pharmacother 34 2000 161 164
16. I. Nestorov, M. Lebsack, T. DeVries, T. Burge Pharmacokinetics of etanercept after once weekly subcutaneous administration of 50 mg doses to rheumatoid arthritis patients 2003 Abstracts of the Annual European Congress of Rheumatology EULAR; Lisbon, Portugal. Poster THU0239.
17. H. Zhou, M. Buckwalter, P.R. Mayer, D. Raible, J. Wajdula, S. Fatenejad Pharmacokinetics (PK) of etanercept are unaltered by concurrent administration of methotrexate (MTX) in rheumatoid arthritis (RA) patients 2003 ACR Annual Scientific Meeting; November; Orlando, FL. Poster 253.
18. H. Lee, H.C. Kimko, M. Rogge, D. Wang, I. Nestorov, C.C. Peck Population pharmacokinetic (PK) and pharmacodynamic (PD) modeling of etanercept using logistic regression analysis Clin Pharmacol Ther 73 2003 348 365
19. H. Zhou, M. Buckwalter, J. Boni, P. Mayer, D. Raible, J. Wajdula Pharmacokinetics (PK) of etanercept ankylosing spondylitis (AS) patients a population-based investigation J Clin Pharmacol 43 2003 1033
20. REMICADE® (Infliximab) Patient Information 2001 Centocor Inc Malvern, PA, USA
21. Y.W. Zhu, M.A. Graham, A. Menter, A.B. Gottlieb Pharmacokinetics of infliximab (REMICADE®) in patients with severe plaque-type psoriasis 62nd AAD Annual Meeting; February 6-11, 2004l; Washington DC Poster abstracts. J Am Acad Dermatol 50 suppl 2004 Poster P617
22. D. DiNoto, K. Mace, R. DeRita, R. Jordan, C. Wagner Pharmacokinetics of infliximab, a chimeric monoclonal antibody specific to tumor necrosis factor clinical studies in rheumatoid arthritis patients 1999 AAPS Annual Meeting; November. Abstract 4733.
23. A. Kavanaugh, E.W. St. Clair, W.J. McCune, T. Braakman, P. Lipsky Chimeric anti-tumour necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy J Rheumatol 27 2000 841 850
24. E.W. St. Clair, C. Wagner, B. Wang, T. Schaible, A. Fasanmade, A.F. Kavanaugh Pharmacokinetics of infliximab therapy for rheumatoid arthritis 2001 ACR Annual Meeting; November. Abstract 970.
25. A.B. Gottlieb, S. Masud, R. Ramamurthi, A. Abdulghani, P. Romano, U. Chaudhari Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris J Am Acad Dermatol 48 2003 68 75
26. A. Markham, H.M. Lamb Infliximab a review of its use in the management of rheumatoid arthritis Drugs 59 2000 1342 1359
27. A.A. Fasanmade, Y.W. Zhu, C. Wagner, C. Pendley, H.M. Davis Population pharmacokinetics of single dose infliximab in patients with Crohn's disease ASCPT 2002 abstracts, abstract TPII-92. Clin Pharmacol Ther 71 2002 P66
28. R.N. Maini, F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Davis, J.D. MacFarlane Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 41 1998 1552 1563
29. J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, W.D. Schwieterman Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent New Engl J Med 345 2001 1098 1104
30. R. Day Adverse reactions to TNF-α inhibitors in rheumatoid arthritis [commentary] Lancet 359 2002 540 541